Claims
- 1. A compound of formula I ##STR17## wherein R.sup.1 and R.sup.2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy;
- Y is >CH--CH.sub.2 -- or >C.dbd.CH-- wherein only the underscored atom participates in the ring system;
- X is --O--, O--CH.sub.2 -- or --CH.sub.2 --O--;
- r is 1, 2 or 3; and
- Z is selected from ##STR18## wherein R.sup.3 is --(CH.sub.2).sub.p COOH wherein p is 2, 3, 4, 5 or 6; or
- a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 wherein R.sup.1 and R.sup.2 independently are hydrogen, halogen, trifluoromethyl or C.sub.1-6 -alkyl.
- 3. A compound of claim 1 wherein X is --O--.
- 4. A compound of claim 1 wherein Z is selected from ##STR19## wherein R.sup.3 is --(CH.sub.2).sub.p COOH and p is 2, 3, 4, 5 or 6.
- 5. A compound of claim 1 wherein p is 2 or 3.
- 6. A compound of claim 1 selected from the following:
- 3-(1-(3-(Xanthen-9-ylidene)-1-propyl)piperidin-4-yl)propionic acid, and
- 3-(1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)piperidin-4-yl)propionic acid,
- or a pharmaceutically acceptable salt thereof.
- 7. A method of preparing a compound of claim 1, comprising: reacting a compound of formula II ##STR20## wherein R.sup.1, R.sup.2, X, Y and r are as defined in claim 1 and W is a suitable leaving group, with a compound of formula III
- wherein Z is as defined in claim 1, to form a compound of formula I.
- 8. A pharmaceutical composition comprising as an active component an effective amount of a compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.
- 9. The pharmaceutical composition of claim 8 comprising between 0.5 mg and 1000 mg of the compound.
- 10. A method of treating neurogenic inflammation comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
- 11. A method of treating neurogenic inflammation comprising administering to a subject in need thereof a pharmaceutical composition according to claim 8.
- 12. A method of treating neurogenic inflammation associated with neuropathy or rheumatoid arthritis comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
- 13. A method of treating neurogenic inflammation associated with neuropathy or rheumatoid arthritis comprising administering to a subject in need thereof a pharmaceutical composition of claim 8.
- 14. A method of treating insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) or ageing-associated obesity comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
- 15. A method of treating insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) or ageing-associated obesity comprising administering to a subject in need thereof a pharmaceutical composition of claim 8.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0751/97 |
Jun 1997 |
DEX |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of application Ser. No. 09/098,579 filed Jun. 17, 198 and claims priority under 35 U.S.C. 119 of Danish application No. 0751/97 filed Jun. 25, 1997 and U.S. provisional application No. 60/051,833 filed Jul. 7, 1997, the contents of which are fully incorporated herein by reference.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5753678 |
Hohlweg et al. |
May 1998 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9518793 |
Jul 1995 |
WOX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
098579 |
Jun 1998 |
|